Although bufalin directly binds and degrades SRC-3 and SRC-1 via the proteasome and blocks cancer cell growth in vitro and in vivo, verrucarin selectively degrades SRC-3 without physically interacting with it and blocks cancer cell proliferation and migration [7, 55, 56]. This evidence concerns the gene SRC and cancer.